NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

Carbagen® (carbamazepine) tablet supply issues

There is currently a national shortage of the Carbagen® brand of carbamazepine 200 and 400mg immediate release (IR) and prolonged release (PR) tablets. The MHRA has classified carbamazepine as a Category 1 antiepileptic drug, which means patients with epilepsy should be maintained on a specific manufacturer’s product.

The only other brand of carbamazepine tablets available is Tegretol® (100, 200 and 400mg IR and 200 and 400mg PR). Novartis have confirmed that there is sufficient stock of Tegretol® to cover the shortfall of Carbagen®, although supply may be subject to temporary interruptions. Any community pharmacist having difficulty in sourcing a Novartis preparation can contact Novartis customer services directly and supplies can be arranged with them.

A memo with details of the supply problem and potential strategies for managing the shortage is available here.

Communication has also been sent to all community pharmacists advising them to contact prescribers if required.


Published 15/03/19. Medicines Update blogs are correct at the time of publication.

We would like to hear what you think of Medicines Update blogs. Please leave us your feedback using this anonymous survey here.